Skip to main content

Research Repository

Advanced Search

Tofacitinib in ulcerative colitis

Archer, Thomas P.; Moran, Gordon W.; Ghosh, Subrata

Authors

Thomas P. Archer

GORDON MORAN GORDON.MORAN@NOTTINGHAM.AC.UK
Professor of Gastroenterology

Subrata Ghosh



Abstract

Cytokines orchestrate immune and inflammatory responses involved in the pathogenesis of ulcerative colitis (UC). Protein kinases are essential for signal transduction in eukaryotic cells. Janus kinases (JAKs) are a family of protein tyrosine kinases that play a pivotal role in cytokine receptor signaling. Indeed, a major subgroup of cytokines use Type I and II cytokine receptors which signal via the activation of JAKs. Tofacitinib is an oral JAK inhibitor that has been studied in autoimmune pathologies, including UC and rheumatoid arthritis with good overall efficacy and acceptable safety profile. This literature review was performed with the goal of summarizing the knowledge on JAK inhibitors in UC treatment.

Journal Article Type Article
Acceptance Date Mar 1, 2016
Online Publication Date May 3, 2016
Publication Date May 3, 2016
Deposit Date Dec 13, 2018
Print ISSN 1750-743X
Publisher Future Medicine
Peer Reviewed Peer Reviewed
Volume 8
Issue 5
DOI https://doi.org/10.2217/imt-2015-0031
Public URL https://nottingham-repository.worktribe.com/output/1413082
Publisher URL https://www.futuremedicine.com/doi/pdf/10.2217/imt-2015-0031